Naproxen vs Diclofenac: Safety and Efficacy Comparison

Cardiovascular Safety Profile

The American Heart Association recommends that naproxen is safer than diclofenac in terms of cardiovascular risk, with a relative risk of 0.92 (95% CI 0.67-1.26) versus placebo, while diclofenac shows a relative risk of 1.63 (95% CI 1.12-2.37) 1
Diclofenac has been associated with increased risk of major coronary events (moderate effect) and serious upper gastrointestinal events (moderate effect), according to the Centers for Disease Control and Prevention 2, 3
Diclofenac lies on the more COX-2 selective end of the spectrum, which explains its higher thrombotic risk profile similar to COX-2 inhibitors, as reported by the American College of Cardiology 4, 5

The American Gastroenterological Association notes that both medications carry risks for gastrointestinal complications, but with different profiles, with naproxen associated with a large increase in risk for serious upper gastrointestinal events, particularly in the first 6 months of treatment 2, 3
Diclofenac shows a moderate effect on risk for serious upper gastrointestinal events, according to the Centers for Disease Control and Prevention 2
Risk factors for NSAID-related GI complications include increasing age, previous GI events, concomitant use of anticoagulation therapy or corticosteroids, as reported by the European Society for Clinical Gastroenterology 6

The American College of Cardiology recommends that both medications should be prescribed at the lowest effective dose for the shortest duration necessary to control symptoms 5, 7
For patients with cardiovascular risk factors, naproxen is preferred over diclofenac based on its more favorable cardiovascular safety profile, according to the American Heart Association 8, 5

For patients with cardiovascular risk factors or established cardiovascular disease, the American College of Cardiology recommends preferring naproxen over diclofenac due to lower cardiovascular risk 8, 1
For patients with gastrointestinal risk factors, the European Society for Clinical Gastroenterology suggests considering co-therapy with proton pump inhibitors for either NSAID 6, 9

The American Gastroenterological Association advises avoiding combining either NSAID with aspirin when possible, as this increases gastrointestinal risk without clear evidence of cardiovascular protection 6, 9
The Centers for Disease Control and Prevention notes that poor compliance with gastroprotective agents can increase the relative risk of NSAID-induced upper GI adverse events 4-6 times 9
The American Heart Association recommends monitoring renal function and blood pressure control, as both medications can affect these parameters 8, 5

The American Heart Association implies that naproxen is the safer choice compared to diclofenac, particularly for patients with cardiovascular risk factors, based on substantially lower cardiovascular mortality and morbidity risk 10, 11
Diclofenac carries significantly higher cardiovascular risk than naproxen across all major endpoints, with a relative risk of 1.63 (95% CI 1.12-2.37) versus placebo for vascular events, and 1.40 (95% CI 1.16-1.70) for cardiovascular events (mostly MI) 10, 11
The American College of Cardiology recommends that diclofenac demonstrates a striking relative risk of 2.40 (95% CI 2.09-2.80) for mortality in registry data, while naproxen shows no significant mortality increase 10, 11
Naproxen demonstrates 36% lower vascular event risk compared to selective COX-2 inhibitors (RR 0.64, 95% CI 0.49-0.83), while non-naproxen NSAIDs (primarily diclofenac) show no protective effect (RR 1.14, 95% CI 0.89-1.45) 10, 11

The American Gastroenterological Association notes that co-administration of omeprazole with diclofenac showed similar rates of recurrent ulcer bleeding as celecoxib 200 mg twice daily in high-risk patients 12

For patients with cardiovascular disease or risk factors, the American Heart Association suggests choosing naproxen at the lowest effective dose (typically ≤1000 mg/day) for the shortest duration necessary 10, 11
The Journal of the American Geriatrics Society recommends avoiding diclofenac entirely in patients with established cardiovascular disease or multiple risk factors 13, 14
Diclofenac is specifically identified as carrying the highest cardiovascular risk among traditional NSAIDs, according to the Journal of the American Geriatrics Society 13, 14

Both agents adversely affect blood pressure control, renal function, and heart failure management, but require different monitoring approaches, as noted by the Journal of the American Geriatrics Society 13, 14